Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on OSE Immunotherapeutics SA (6OP – Research Report) on March 12 and set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback